AbbVie (ABBV) vs Novartis (NVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbbVie (ABBV) has outperformed Novartis (NVS) over the past year, gaining 21.1% versus a gain of 18.2%. Over five years, ABBV leads with a +145.6% price change compared with +86.5% for NVS. AbbVie is the larger company by market cap ($505.89 billion vs $284.18 billion), about 1.8 times the size.
On valuation, Novartis trades at a lower forward P/E (15.1x vs 17.6x for AbbVie). Novartis offers the higher dividend yield (3.10% vs 2.42%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | NVS |
|---|---|---|
| Share price | $286.20 | $150.47 |
| Market cap | $505.89B | $284.18B |
| 1-day change | +0.94% | -0.50% |
| YTD return | +25.26% | +9.14% |
| 1-year return | +21.13% | +18.19% |
| 5-year return | +145.64% | +86.46% |
| P/E ratio (TTM) | 49.18 | 28.72 |
| Forward P/E | 17.65 | 15.15 |
| EPS (TTM) | $5.82 | $5.24 |
| Dividend yield | 2.42% | 3.10% |
| Annual dividend | $6.92 | $4.67 |
| Revenue (latest FY) | $61.16B | — |
| Revenue growth (YoY) | +8.57% | — |
| Net income (latest FY) | $4.23B | $13.98B |
| Gross margin | 70.24% | — |
| Operating margin | 24.65% | — |
| Net margin | 6.91% | — |
| 52-week high | $302.93 | $170.46 |
| 52-week low | $190.75 | $126.50 |
| Distance from 52-week high | -5.52% | -11.73% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +9.76% | +4.41% |
| Average volume | 4.84M | 2.18M |
| Shares outstanding | 1.77B | 1.89B |
| Employees | 57,000 | 75,267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AbbVie trades at a higher earnings multiple (49.2x vs 28.7x trailing P/E).
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
ABBV vs NVS FAQ
Which is bigger, AbbVie or Novartis?
AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $284.18B for Novartis (NVS).
Which stock has performed better over the past year, ABBV or NVS?
ABBV returned +21.13% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or NVS?
NVS has the lower trailing P/E at 28.7, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or Novartis?
Novartis has the higher yield at 3.10%, compared with 2.42% for AbbVie.
Are AbbVie and Novartis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.